Clinical Development of Antiepileptic Drugs for Children

Neurotherapeutics

Volumn 4, Issue 1, 2007, Pages 70-74

  Garofalo, Elizabeth ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

antiepileptic drugs; children; clinical development; Epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; PLACEBO;

ARTICLE; BENIGN CHILDHOOD EPILEPSY; CHILD; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DRUG DOSE REGIMEN; DRUG LEGISLATION; DRUG MONITORING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTROENCEPHALOGRAM; EPILEPSY; FOLLOW UP; HUMAN; INFANTILE SPASM; LENNOX GASTAUT SYNDROME; MEDICAL ETHICS; OBSERVATIONAL STUDY; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; ROLANDIC EPILEPSY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DRUG EVALUATION; EPILEPSY; HUMANS; INFANT; INFANT, NEWBORN;

EID: 33846210071     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2006.10.004     Document Type: Article

References (28)

1. Pellock J.M. Pediatric trials: practical issues. Special populations and trial designs. Adv Neurol 76 (1998) 167-171
2. Guidance for Industry: E11 clinical investigation of medicinal products in the pediatric population. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. December 2000. Available at: http://www.fda.gov/cder/guidance/4099fnl.pdf.
3. Best Pharmaceuticals for Children Act (BPCA). Public Law 107-109. January 4, 2002. Available at: http://thomas.loc.gov/bss/d107/d107laws.html.
4. Pediatric Research Equity Act (PREA). Public Law 108-155. December 3, 2003. Available at: http://thomas.loc.gov/bss/d108/d108laws.html.
5. Additional safeguards for children in clinical investigations of FDA-regulated products. U.S. Department of Health and Human Services, Food and Drug Administration. April 2001. 66 Federal Register 20589-20600. Available at: http://www.fda.gov/ohrms/dockets/98fr/042401a.htm.
6. Commission on Antiepileptic Drugs of the International League of Epilepsy. Workshop on antiepileptic drug trials in children. Epilepsia 32 (1991) 284-285
7. Sheridan P.H., and Jacobs M.P. The development of antiepileptic drugs for children. Report from the NIH workshop, Bethesda, Maryland, February 17-18, 1994. Epilepsy Res 23 (1996) 87-92
8. European Medicines Agency (Paediatric Working Party, Quality Working Party). Reflection paper: formulations of choice for the paediatric population. EMEA/CHMP/PEG/194810/2005. London: European Medicines Agency, 2006. Available at: http://www.emea.europa.eu/pdfs/human/peg/19481005en.pdf.
9. Ouellet D., Bockbrader H.N., Wesche D.L., Shapiro D.Y., and Garofalo E. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res 47 (2001) 229-241
10. Hauser W.A. The prevalence and incidence of convulsive disorders in children. Epilepsia 35 Suppl 2 (1994) S1-S6
11. Camfield P.R., Camfield C.S., Gordon K., and Dooley J.M. If a first antiepileptic drug fails to control a child's epilepsy, what are the chances of success with the next drug?. J Pediatr 131 (1997) 821-824
12. Korff C., and Nordli D.R. Do generalized tonic-clonic seizures in infancy exist?. Neurology 65 (2005) 1750-1753
13. Wyllie E. The treatment of epilepsy: principles and practice. 4th ed. (2006), Lippincott Williams and Wilkins, Philadelphia, PA
14. Sullivan III J.E., and Dlugos D.J. Antiepileptic drug monotherapy: pediatric concerns. Semin Pediatric Neurol 12 (2005) 88-96
15. U.S. Department of Health and Human Services Food and Drug Administration. Summaries of medical and clinical pharmacology reviews of pediatric studies [Internet]. Created June 18, 2003; updated periodically. Accessed June 19, 2006. Available at: http://www.fda.gov/cder/pediatric/Summaryreview.htm.
16. Sahlroot J.T., and Pledger G.W. Reanalysis of existing trial data: what can be learned. Adv Neurol 76 (1998) 125-131
17. Pina-Garza J.E., Espinoza R., Nordli D., et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology 65 (2005) 1370-1375
18. Nordli D.R. Diagnostic difficulty in infants and children. J Child Neurol 17 (2002) S28-S35
19. Motte J., Trevathan E., Arvidsson J.F.V., et al. ; Lamictal Lennox-Gastaut Study Group. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 337 (1997) 1807-1812 [Erratum in: N Engl J Med 1998;339:851-852]
20. Sachdeo R.C., Glauser T.A., Ritter F., Reife R., Lim P., and Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 52 (1999) 1882-1887
21. Biton V., Sackellares J.C., Vuong A., Hammer A.E., Barrett P.S., and Messenheimer J.A. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 65 (2005) 1737-1743
22. Bourgeois B., Brown L., Pellock J.M., et al. Gabapentin (Neurontin®) monotherapy in children with benign childhood epilepsy with centrotemporal spikes (BECTS): a 36-week, double-blind, placebo-controlled study. Epilepsia 39 (1998) 163 Abstract
23. Frank L.M., Enlow T., Holmes G.L., et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 40 (1999) 973-979
24. Trudeau V., Myers S., LaMoreaux L., Anhut H., Garofalo E., and Ebersole J. Gabapentin in naïve childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 11 (1996) 470-475
25. Mackay M.T., Weiss S.K., Adams-Webber T., et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 62 (2004) 1668-1681
26. Shinnar S., and Pellock J.M. The trials and tribulations of pediatric drug trials. Neurology 65 (2005) 1348-1349
27. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs. II. Treatment of refractory epilepsy. Report of the Therapeutic and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1261-1273
28. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs. I. Treatment of new onset epilepsy. Report of the Therapeutic and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1252-1260